Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples